{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:27:38Z","timestamp":1786724858233,"version":"build-2736575974"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100003323","name":"ANRS|MIE and CHU de Bordeaux","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc.","doi-asserted-by":"publisher","award":["CO-FR-380-6386"],"award-info":[{"award-number":["CO-FR-380-6386"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We investigated, in a real-world setting, virological factors associated with virological failure (VF) after bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) initiation in people with HIV (PWH) with and without pre-existing drug resistance mutation (PRM) and the emergence of new resistance mutations at virological failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Treatment-experienced PWH from ANRS-CO3-AquiVIH-NA cohort starting B\/F\/TAF between 2018 and 2021 were stratified depending on their baseline viral load (VL): virologically suppressed (VS; VL &amp;lt;50\u2005copies\/mL) and virologically unsuppressed (VU; VL &amp;gt;50\u2005copies\/mL). PRM were identified using cumulative genotypic resistance tests (GRT) according to the ANRS algorithm. Factors associated with VF were analysed using a Cox proportional hazards model and survival curves.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 636 PWH with available GRT results, 82.7% were VS at B\/F\/TAF initiation. PRMs to at least one component of B\/F\/TAF were present for 23.1% of participants (20.9% VS and 33.6% VU), with the M184I\/V mutation identified in 89.1% of cases (88.2% in VS and 91.9% in VU). Virological success was higher for those with no PRMs (92.8% no PRM vs 86.4% with PRM). VU PWH had a higher risk of VF [HR 9.53 (5.54\u201316.40)]. Among the 66 PWH with baseline GRT experiencing VF, new resistance mutations were selected for six (two VU and four VS). After VF, B\/F\/TAF was maintained for 56\/66 (84.8%) participants, of whom 40\/56 (71.4%) had a VL &amp;lt;50\u2005copies\/mL at their last visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Virological suppression was maintained in VS PWH regardless PRMs but to a less extent in VU PWH. Emergence of new resistance mutation occurred rarely in the case of VF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag278","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:50:13Z","timestamp":1785498613000},"source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with virological failure in people with HIV treated with bictegravir\/emtricitabine\/tenofovir alafenamide. Impact of pre-existing mutations and risk of resistance emergence.\n                    <i>ANRS-CO3-AquiVIH-NA cohort<\/i>"],"prefix":"10.1093","volume":"81","author":[{"given":"Pantxika","family":"Bellecave","sequence":"first","affiliation":[{"name":"CHU Bordeaux, Service de Virologie, H\u00f4pital Pellegrin , Bordeaux 33076 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaric","family":"Peyrouny-Mazeau","sequence":"additional","affiliation":[{"name":"Bordeaux Population Health Research Center, INSERM U1219, CIC-EC 1401, Univ. Bordeaux\u2014ISPED , Bordeaux 33076 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Leleux","sequence":"additional","affiliation":[{"name":"Bordeaux Population Health Research Center, INSERM U1219, CIC-EC 1401, Univ. Bordeaux\u2014ISPED , Bordeaux 33076 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojgan","family":"Hessamfar","sequence":"additional","affiliation":[{"name":"Bordeaux Population Health Research Center, INSERM U1219, CIC-EC 1401, Univ. Bordeaux\u2014ISPED , Bordeaux 33076 ,","place":["France"]},{"name":"CHU de Bordeaux, Service de M\u00e9decine Interne et Maladies Infectieuses, H\u00f4pital Saint-Andr\u00e9 , Bordeaux 33075 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00ebl","family":"Le Moal","sequence":"additional","affiliation":[{"name":"CHU de Poitiers, Service de Maladies Infectieuses et Tropicales , Poitiers 86000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Neau","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Service de Maladies Infectieuses et Tropicales , H\u00f4pital Pellegrin, Bordeaux 33076 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Alleman","sequence":"additional","affiliation":[{"name":"CH de la C\u00f4te Basque, Service de Maladies Infectieuses , Bayonne 64100 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Cazanave","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Service de Maladies Infectieuses et Tropicales , H\u00f4pital Pellegrin, Bordeaux 33076 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estibaliz","family":"Lazaro","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Service de M\u00e9decine Interne et Maladies Infectieuses , H\u00f4pital Haut-L\u00e9v\u00eaque, Pessac 33600 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Duffau","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Service de M\u00e9decine Interne et Maladies Infectieuses, H\u00f4pital Saint-Andr\u00e9 , Bordeaux 33075 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4382-4849","authenticated-orcid":false,"given":"Marie-Anne","family":"Vandenhende","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Service de M\u00e9decine Interne et Maladies Infectieuses, H\u00f4pital Saint-Andr\u00e9 , Bordeaux 33075 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Castan","sequence":"additional","affiliation":[{"name":"CH de P\u00e9rigueux, Service de Maladies Infectieuses et Tropicales , P\u00e9rigueux 24000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Tumiotto","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Service de Virologie, H\u00f4pital Pellegrin , Bordeaux 33076 ,","place":["France"]},{"name":"CNRS-UMR 5234 Microbiologie Fondamentale et Pathog\u00e9nicit\u00e9, Universit\u00e9 de Bordeaux , Bordeaux 33000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-4178","authenticated-orcid":false,"given":"Fabrice","family":"Bonnet","sequence":"additional","affiliation":[{"name":"Bordeaux Population Health Research Center, INSERM U1219, CIC-EC 1401, Univ. Bordeaux\u2014ISPED , Bordeaux 33076 ,","place":["France"]},{"name":"CHU de Bordeaux, Service de M\u00e9decine Interne et Maladies Infectieuses, H\u00f4pital Saint-Andr\u00e9 , Bordeaux 33075 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"2026081411010273700_dkag278-B1","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"2026081411010273700_dkag278-B2","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380\u20131490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2026081411010273700_dkag278-B3","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials","volume":"7","author":"Orkin","year":"2020","journal-title":"Lancet HIV"},{"key":"2026081411010273700_dkag278-B4","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48\u2005week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"2026081411010273700_dkag278-B5","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","article-title":"Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48\u2005week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial","volume":"5","author":"Daar","year":"2018","journal-title":"Lancet HIV"},{"key":"2026081411010273700_dkag278-B6","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus","volume":"73","author":"Sax","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026081411010273700_dkag278-B7","author":"Department of Health and Human Services"},{"key":"2026081411010273700_dkag278-B8","author":"European AIDS Clinical Society"},{"key":"2026081411010273700_dkag278-B9","author":"ANRS-MIE"},{"key":"2026081411010273700_dkag278-B10","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1093\/jac\/dkz347","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184\u2005V\/I","volume":"74","author":"Andreatta","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026081411010273700_dkag278-B11","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1097\/QAD.0000000000003244","article-title":"High ef\ufb01cacy of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in people with suppressed HIV and preexisting M184V\/I","volume":"36","author":"Sax","year":"2022","journal-title":"AIDS"},{"key":"2026081411010273700_dkag278-B12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jgar.2022.06.027","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice","volume":"30","author":"Armenia","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"2026081411010273700_dkag278-B13","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf087","article-title":"Three-year effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide as a switch strategy in the real world","volume":"12","author":"De Gea-Grela","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026081411010273700_dkag278-B14","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1111\/hiv.13690","article-title":"Evaluation of HIV antiretroviral treatment adherence in 2019 using anonymized data from the French national health insurance claims data base: the COCOVIH study","volume":"25","author":"Prevoteau du Clary","year":"2024","journal-title":"HIV Med"},{"key":"2026081411010273700_dkag278-B15","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1093\/jac\/dkae138","article-title":"Effectiveness, safety and discontinuation rates of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) in people with HIV using real-world data: a systematic review and meta-analysis","volume":"79","author":"Chivite","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026081411010273700_dkag278-B16","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/jac\/dkae081","article-title":"Long-term outcomes of bictegravir\/emtricitabine\/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort","volume":"79","author":"d\u2019Arminio Monforte","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026081411010273700_dkag278-B17","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1093\/jac\/dkaf357","article-title":"From TRIO to one: simplification to bictegravir\/emtricitabine\/tenofovir alafenamide in highly treatment-experienced people living with MDR HIV","volume":"80","author":"Casado","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026081411010273700_dkag278-B18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ijid.2022.11.012","article-title":"Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N\/R mutation","volume":"126","author":"Tsai","year":"2023","journal-title":"Int J Infect Dis"},{"key":"2026081411010273700_dkag278-B19","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1097\/QAD.0000000000003311","article-title":"Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide in treatment experience patients","volume":"36","author":"Mic\u00e1n","year":"2022","journal-title":"AIDS"},{"key":"2026081411010273700_dkag278-B20","doi-asserted-by":"publisher","DOI":"10.1080\/25787489.2025.2456890","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort","volume":"26","author":"Trottier","year":"2025","journal-title":"HIV Res Clin Pract"},{"key":"2026081411010273700_dkag278-B21","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1093\/jac\/dkab115","article-title":"Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide in HIV-1 treatment-naive participants","volume":"76","author":"Acosta","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026081411010273700_dkag278-B22","doi-asserted-by":"publisher","DOI":"10.1177\/13596535241306467","article-title":"Effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) as switch strategy in virologically-suppressed patients: real world data from a monocentric cohort","volume":"29","author":"Passerotto","year":"2024","journal-title":"Antivir Ther"},{"key":"2026081411010273700_dkag278-B23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/hiv.13376","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in patients with genotypic NRTI resistance","volume":"24","author":"Shafran","year":"2023","journal-title":"HIV Med"},{"key":"2026081411010273700_dkag278-B24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/jac\/dkq544","article-title":"Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia","volume":"66","author":"Wirden","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2026081411010273700_dkag278-B25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/j.1468-1293.2012.01002.x","article-title":"Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication","volume":"13","author":"Delaugerre","year":"2012","journal-title":"HIV Med"},{"key":"2026081411010273700_dkag278-B26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/jac\/dkae377","article-title":"Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the virostar-1 study","volume":"80","author":"Marcelin","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026081411010273700_dkag278-B27","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/hiv.13493","article-title":"Efficacy, durability, and tolerability of bictegravir\/emtricitabine\/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium","volume":"24","author":"Nasreddine","year":"2023","journal-title":"HIV Med"},{"key":"2026081411010273700_dkag278-B28","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/QAD.0000000000004438","article-title":"Antiretroviral resistance in at least second-line HIV-1 treatment virologic failure with common InSTI-based regimens","volume":"40","author":"Marcelin","year":"2026","journal-title":"AIDS"},{"key":"2026081411010273700_dkag278-B29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/jac\/dkae407","article-title":"Efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy","volume":"80","author":"Andreatta","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026081411010273700_dkag278-B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-67837-6","article-title":"Relationship between adherence to bictegravir\/emtricitabine\/tenofovir alafenamide fumarate and clinical outcomes in people with HIV in Japan: a claims database analysis","volume":"14","author":"Taguchi","year":"2024","journal-title":"Sci Rep"},{"key":"2026081411010273700_dkag278-B31","doi-asserted-by":"publisher","DOI":"10.1177\/23259582221140208","article-title":"Real world data on forgiveness to uncomplete adherence to bictegravir\/emtricitabine\/tenofovir alafenamide","volume":"21","author":"Maggiolo","year":"2022","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2026081411010273700_dkag278-B32","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1016\/S2352-3018(21)00300-3","article-title":"A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial","volume":"9","author":"Landman","year":"2022","journal-title":"Lancet HIV"},{"key":"2026081411010273700_dkag278-B33","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1093\/jac\/dky316","article-title":"Utility of HIV-1 DNA genotype in determining antiretroviral resistance in patients with low or undetectable HIV RNA viral loads","volume":"73","author":"Boukli","year":"2018","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/9\/dkag278\/70651613\/dkag278.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/9\/dkag278\/70651613\/dkag278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T15:29:24Z","timestamp":1786721364000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag278\/8761753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag278","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,4]]},"article-number":"dkag278"}}